CLOs on the Move

Amneal

www.amneal.com

 
Amneal (NYSE:AMRX) is building one of the most dynamic pharmaceutical companies in our industry. Today`s healthcare environment requires new ideas. While staying true to our reputation for quality, service and value in pharmaceuticals, we are challenging ourselves, our playbook and the status quo. We are uniting people, passion and products to deliver outcomes that meet important medical needs, make quality medicines more accessible and more affordable, and provide solutions for tomorrow`s health challenges. We are Amneal and “We make healthy possible.” Learn more about how we`re making a difference in generics, brands and biosimilars at Amneal.com.
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion
  • www.amneal.com
  • 400 Crossing Boulevard 3rd Floor
    Bridgewater, NJ USA 08807
  • Phone: 908.947.3120

Executives

Name Title Contact Details
Jason Daly
 Executive Vice President | Chief Legal Officer Profile
Meredith Cook
 Vice President and Associate General Counsel Profile
Stephen Manzano
 Senior Vice President, General Counsel and Secretary Profile
Leslie Restaino
 Chief Compliance Officer Profile
Christa Haskins
 Associate Director, E-Discovery Profile

Similar Companies

ChemCon America

ChemCon America is a Lake Mary, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Argentis Pharmaceuticals

arGentis™ Pharmaceuticals, LLC is a private TN based pharmaceutical company with a mid-stage Orphan Drug treatment (ARG201) for late stage diffuse systemic scleroderma (dcSSc). The company is seeking capital or a partner to complete a Pivotal Clinical Trial which will enable obtaining marketing approval in the EU. The Company has a genotype marker (ROT1) that predicts patient response to treatment by oral tolerance for treatments like ARG201 for dcSSc. Furthermore, arGentis™ has a treatment for Rheumatoid arthritis (ARG301) that is in a Phase I Clinical Trial in the US.

Tobira Therapeutics

Tobira Therapeutics is a clinical-stage biopharmaceutical company developing cenicriviroc (CVC), an oral potent dual inhibitor of chemokine receptors CCR2 and CCR5. Tobira is initiating a Phase 2 clinical trial of cenicriviroc for the treatment of Nonalcoholic Steatohepatitis (NASH), a leading cause of cirrhosis and liver transplant. The company has also completed a Phase 2b clinical trial of cenicriviroc in 143 HIV-infected subjects, and the compound is positioned for Phase 3 studies as a novel, once daily, fixed-dose cenicriviroc/lamivudine backbone as part of combination HIV therapy. Tobira is backed by a syndicate of leading life science investors including Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners, Novo Ventures and Canaan Partners.

Porzio Life Sciences

Regulatory compliance software solutions, products and services assist pharmaceutical, medical device and biotechnology companies in complying with marketing and sales regulations.

Adjuvants Plus Inc

Adjuvants Plus Inc is a Kingsville, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.